1,356,397 Illumina, Inc. $ILMN Shares Acquired by Ninety One UK Ltd

Ninety One UK Ltd boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 37,920.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,359,974 shares of the life sciences company’s stock after purchasing an additional 1,356,397 shares during the quarter. Ninety One UK Ltd owned about 0.90% of Illumina worth $372,198,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ILMN. Fiduciary Financial Advisors bought a new position in Illumina in the 2nd quarter valued at about $26,000. MCF Advisors LLC raised its position in shares of Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after buying an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at approximately $32,000. Rakuten Securities Inc. bought a new stake in shares of Illumina during the 2nd quarter worth approximately $33,000. Finally, Elevation Wealth Partners LLC lifted its holdings in shares of Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after acquiring an additional 84 shares during the period. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the topic of several analyst reports. Royal Bank Of Canada increased their price target on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Leerink Partners lifted their price objective on shares of Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Barclays upped their target price on Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a research note on Wednesday, October 7th. Finally, Piper Sandler upped their target price on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $225.94.

Illumina Price Performance

NASDAQ:ILMN traded down $1.60 during trading hours on Thursday, hitting $270.16. The company’s stock had a trading volume of 1,379,613 shares, compared to its average volume of 2,167,091. Illumina, Inc. has a twelve month low of $93.50 and a twelve month high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a fifty day simple moving average of $231.55 and a 200-day simple moving average of $184.42. The company has a market capitalization of $40.79 billion, a P/E ratio of 50.23, a PEG ratio of 3.84 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the sale, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. The trade was a 13.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.